Renal Tumour Imaging Using MRI

NCT ID: NCT07173140

Last Updated: 2025-09-15

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Clinical Phase

NA

Total Enrollment

30 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-11-20

Study Completion Date

2025-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study investigates whether new types of MRI scans can tell the difference between different kidney tumours before surgery. Currently, imaging scans can detect kidney tumours and their size, but they aren't effective at determining the tumour type or its aggressiveness. Biopsies are an option, but they are invasive and may miss important cancerous cells. The aim is to use imaging to determine which tumours are aggressive so they can be treated early while avoiding unnecessary treatment of benign tumours.

Patients with small renal tumours (≤ 7 cm) who meet the other inclusion and exclusion criteria will be asked to have an additional MRI scan at University College London Hospital prior to surgery.

The imaging findings will be compared to the histology result from the removed tumour. In 10 patients the histology will be targeted to a specific location in the tumour based on the imaging. 10 patients will undergo a repeat MRI \<14 d apart to test whether the MRI scans can give the same answer twice (the test repeatability).

The study is expected to run for 24 months and is funded by NIHR.

The chief investigator for the study is Dr Richard Hesketh ([email protected]).

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Renal Cancer MRI Small Renal Mass Kidney Cancers

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Scan readers are blinded to lesion histology at the time of region of interest (ROI) drawing

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Histological characterisation of renal tumours

Histological samples of ten patients with tumour histology will be retreived from the Royal Free Hospital Biobank. Slides will be stained using H\&E and CD34 and cell size, stromal space and vascularity will be estimated and used to inform diffusion weighted imaging models.

Group Type NO_INTERVENTION

No interventions assigned to this group

Comparison of microstructural MRI to histology

10 patients with small renal tumours will undergo microstructural MRI. Following MRI the tumours will be surgically resected. The MRI will be co-registered with histology. The degree of correlation between the MRI and underlying histology will be determined.

Group Type EXPERIMENTAL

MRI

Intervention Type DIAGNOSTIC_TEST

Participants undergo an additional MRI scan using novel MRI sequences

Repeatability of MRI of small renal masses

The repeatability of the MRI scan of the small renal mass will be determined by participants undergoing a repeat MRI examination shortly after the first (within 14 d) on the same scanner.

Group Type EXPERIMENTAL

MRI

Intervention Type DIAGNOSTIC_TEST

Participants undergo an additional MRI scan using novel MRI sequences

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

MRI

Participants undergo an additional MRI scan using novel MRI sequences

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Aged 18 and over
2. Confirmed renal tumour ≤ 7 cm planned for surgical resection
3. Willing and able to provide written informed consent
4. Able to lie supine for the duration of an MRI

Exclusion Criteria

1. Contraindication to MRI e.g., cardiac pacemaker
2. Contraindication to MR contrast agents
3. Pregnancy
4. Breastfeeding
5. Deranged renal function (eGFR \<30) in the last three months.
6. Previous treatment of the renal tumour e.g., ablation, radiotherapy
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Royal Free Hospital NHS Foundation Trust

OTHER

Sponsor Role collaborator

University College London Hospitals

OTHER

Sponsor Role collaborator

University College, London

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University College London

London, , United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United Kingdom

Provided Documents

Download supplemental materials such as informed consent forms, study protocols, or participant manuals.

Document Type: Study Protocol

View Document

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

162190

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

MRI in Diagnosing Solid Tumors of the Eye and Orbit
NCT01653080 ACTIVE_NOT_RECRUITING NA
RGD-PET-CT in Cancer Angiogenesis
NCT01492192 TERMINATED PHASE2
GlucoCEST MRI in Oncology
NCT03212157 COMPLETED NA